Finanzen von Revelation Biosciences Inc (REVB)REVBRevelation Biosciences Inc

Evaluating the bottom line, Revelation Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.67%, provide a clear picture of how effectively REVB converts its operational activities into shareholder value.

In the context of the broader market, REVB competes directly with industry leaders such as DCOY and CLDI. With a market capitalization of $2.10M, it holds a significant position in the sector. When comparing efficiency, REVB's gross margin of N/A stands against DCOY's 100.00% and CLDI's N/A. Such benchmarking helps identify whether Revelation Biosciences Inc is trading at a premium or discount relative to its financial performance.

Revelation Biosciences has reported consistent net losses, with a net loss of $59.76 million for FY 2025 and a GAAP EPS of -5.92 for Q3 2026. The current ratio is strong at 6.21, indicating good short-term financial health, but the overall financial performance remains weak due to ongoing losses.